Dr. Rajen Mody, MD, MS
Claim this profileC S Mott Children's Hospital
Expert in Neuroblastoma
Expert in Cancer
52 reported clinical trials
85 drugs studied
About Rajen Mody, MD, MS
Education:
- Earned an MD (Doctor of Medicine).
- Holds an MS (Master of Science).
Experience:
- Serves as Division Chief and Fellowship Program Director at the Pediatric Hematology/Oncology Fellowship Program, C.S. Mott Children's Hospital, University of Michigan.
- Recognized for expertise in pediatric hematology and oncology, covering both non-malignant and malignant disorders.
- Instrumental in developing a fellowship program aimed at nurturing future scientific investigators in pediatric hematology.
- Engages in cutting-edge research and clinical care, including precision medicine and genomic sequencing, for children.
Area of expertise
1Neuroblastoma
Global LeaderMYC positive
Stage IV
BRD4 positive
2Cancer
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Rajen Mody, MD, MS is currently running
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
More about Rajen Mody, MD, MS
Clinical Trial Related8 years of experience running clinical trials · Led 52 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Rajen Mody, MD, MS has experience with
- Dinutuximab
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
- Cyclophosphamide
- Temozolomide
- Larotrectinib
Breakdown of trials Rajen Mody, MD, MS has run
Neuroblastoma
Cancer
Solid Tumors
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rajen Mody, MD, MS specialize in?
Rajen Mody, MD, MS focuses on Neuroblastoma and Cancer. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Rajen Mody, MD, MS currently recruiting for clinical trials?
Yes, Rajen Mody, MD, MS is currently recruiting for 12 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Rajen Mody, MD, MS has studied deeply?
Yes, Rajen Mody, MD, MS has studied treatments such as Dinutuximab, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis.
What is the best way to schedule an appointment with Rajen Mody, MD, MS?
Apply for one of the trials that Rajen Mody, MD, MS is conducting.
What is the office address of Rajen Mody, MD, MS?
The office of Rajen Mody, MD, MS is located at: C S Mott Children's Hospital, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the C S Mott Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.